CONTERA PHARMA A/S: Financial statements 2018
CVR: 33062214
Source: annual report 2018, Danish Business Authority
01/01/2018 – 31/12/2018
CONTERA PHARMA A/S (CVR 33062214) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 1,519,395 and a net result of DKK -967,629 compared with DKK -418,534 the year before. That is an increase of 7.1% compared with the year before. Equity in the 2018 report amounted to DKK 3,202,731. The solvency ratio was 88%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 1,519,395
- Profit/Loss
- DKK -967,629
- Equity
- DKK 3,202,731
- Total Assets
- DKK 3,638,605
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | 1.5 mio. | -968 t. | 3.2 mio. | 2 |
| 2017 | - | 1.4 mio. | -419 t. | 1 mio. | 2 |
| 2016 | - | 3.1 mio. | 866 t. | 1.5 mio. | - |
| 2015 | - | 445 t. | -1.1 mio. | 601 t. | - |
| 2014 | - | -126 t. | -3.2 mio. | 1.7 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2018
As of June 30, 2018, Mikael Søndergaard Thomsen has stepped down as director of CONTERA PHARMA A/S.
CONTERA PHARMA A/S has published its annual report for 2017. Gross profit came to DKK 1,418,538, and the net result was DKK -418,534.
About CONTERA PHARMA A/S
CONTERA PHARMA A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CONTERA PHARMA ApS and CONCIT PHARMA ApS. The management consists of Thomas Nikolaj Sager. The board consists of Jae Young Lee (chair), Jee Hun Kim, Paul Ejnar Gremaud Kristjansen and Thomas Nikolaj Sager. The company is owned by Bukwang Pharmaceutical Co., Ltd. The company has 1 employee (2018). In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity in the 2025 report amounted to DKK 79,471,802.